Researchers at UCD

Emma Rebecca Dorris

Post Doc Research Fellow Lvl I

School Of Medicine & Medical Science



2013- Present  Post-Doc Research Fellow, School of Medicine and Medical Sciences ,Conway Institute, UCD 
2008-2012 Ph.D. in Molecular Medicine, School of Medicine, Institute of Molecular Medicine, Trinity College Dublin
2009-2010  Postgraduate Diploma in Statistics, School of Computer Science & Statistics, Trinity College Dublin




Peer Reviewed Journals

Declan Madsen, Emma R. Cantwell, Timothy O'Brien, Patricia A. Johnson and Bernard P. Mahon (2009) 'Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1'. Journal of General Virology, . [Details]
Emma R. Cantwell-Dorris, John J. O'Leary and Orla M. Sheils (2011) 'BRAFV600E: Implications for Carcinogenesis and Molecular Therapy'. Molecular Cancer Therapeutics, . [Details]
Stephen H.-F. Macdonald, Elliott Woodward, Michelle M. Coleman, Emma R. Dorris, Parthiban Nadarajan, Wui-Mei Chew, Anne-Marie McLaughlin, and Joseph Keane (2012) 'Networked T Cell Death following Macrophage Infection by Mycobacterium tuberculosis'. PLoS ONE, . [Details]
Emma R. Dorris, Paul Smyth, John J. O¿Leary and Orla Sheils (2012) 'MIR141 expression differentiates Hashimoto thyroiditis from PTC and benign thyrocytes in Irish archival thyroid tissues'. Frontiers in endocrinology, . [Details]


Research Interests

I am working on the Molecular Therapeutics for Cancer in Ireland (MTCI) work package 4 investigating molecular determinants of apoptotic resistance in androgen-resistant prostate cancer.  My research focuses on understanding the central signalling pathways and transcription factors underlying the androgen-resistant phenotype with the aim of developing a more appropriate therapeutic targeting approach.

I hold a PhD in Molecular Medicine from the University of Dublin, Trinity College. The focus during my PhD was in transcriptional profiling to identify mechanisms of resistance to molecularly targeted therapeutics of cancer. I had a particular focus on small non-coding RNAs and next generation sequencing and have worked in a lab placement at the European Next Generation Sequencing Headquarters of Applied Biosciences/Life Technologies.